

## **LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**  
**Outer carton, pack size of 1, 2, 3, 4, 6 or 21 pipettes.**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Prinovox 100 mg + 25 mg spot-on solution for medium dogs  
Imidacloprid, Moxidectin

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each 1.0 ml pipette contains 100.0 mg imidacloprid and 25.0 mg moxidectin as active substances.

**3. PHARMACEUTICAL FORM**

Spot-on solution

**4. PACKAGE SIZE**

1 pipette  
2 pipettes  
3 pipettes  
4 pipettes  
6 pipettes  
21 pipettes

**5. TARGET SPECIES**

For medium dogs weighing between 4 kg and 10 kg.

**6. INDICATION(S)**



Fleas



Worms  
(incl. lungworm)



Mites

For dogs suffering from, or at risk from, mixed parasitic infections:

- the treatment and prevention of flea infestation (*Ctenocephalides felis*),
- the treatment of biting lice (*Trichodectes canis*),
- the treatment of ear mite infestation (*Otodectes cynotis*), sarcoptic mange (caused by *Sarcoptes scabiei* var. *canis*), demodicosis (caused by *Demodex canis*),
- the prevention of heartworm disease (L3 and L4 larvae of *Dirofilaria immitis*),
- the treatment of circulating microfilariae (*Dirofilaria immitis*),
- the treatment of cutaneous dirofilariosis (adult stages of *Dirofilaria repens*),

- the prevention of cutaneous dirofilariosis (L3 larvae of *Dirofilaria repens*),
  - the reduction of circulating microfilariae (*Dirofilaria repens*),
  - the prevention of angiostrongylosis (L4 larvae and immature adults of *Angiostrongylus vasorum*),
  - the treatment of *Angiostrongylus vasorum* and *Crenosoma vulpis*,
  - the prevention of spirocercosis (*Spirocerca lupi*),
  - the treatment of *Eucoleus* (syn. *Capillaria*) *boehmi* (adults),
  - the treatment of the eye worm *Thelazia callipaeda* (adults),
  - the treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of *Toxocara canis*, *Ancylostoma caninum* and *Uncinaria stenocephala*, adults of *Toxascaris leonina* and *Trichuris vulpis*).
- The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

## 7. METHOD AND ROUTE(S) OF ADMINISTRATION

For external use only.

Read the package leaflet before use.

## 8. WITHDRAWAL PERIOD(S)

Not applicable

## 9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

Do not use in puppies under 7 weeks of age. Consult your veterinarian before using the product on pregnant or lactating bitches, or on sick or debilitated dogs.

## 10. EXPIRY DATE

EXP {month/year}

## 11. SPECIAL STORAGE CONDITIONS

Do not store above 25 °C.

## 12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

The product should not enter water courses as this may be dangerous for fish and other aquatic organisms.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only - to be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Marketing authorisation holder:  
Elanco Europe Ltd.  
Form 2, Bartley Way  
Bartley Wood Business Park  
Hook  
RG27 9XA  
United Kingdom

Distributed by:  
Virbac Limited  
Woolpit Business Park  
Windmill Avenue  
Woolpit, Bury St Edmunds  
Suffolk  
IP30 9UP

Manufacturer responsible for batch release:  
KVP Pharma + Veterinär Produkte GmbH  
Projensdorfer Str. 324, 24106 Kiel  
Germany

**16. MARKETING AUTHORISATION NUMBER(S)**

Vm 00879/4153

**17. MANUFACTURER'S BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

Pipette label

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Prinovox spot-on for medium dogs

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Imidacloprid(e) 100.0 mg, Moxidectin 25.0 mg

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

1.0 ml

**4. ROUTE(S) OF ADMINISTRATION**

**5. WITHDRAWAL PERIOD**

**6. BATCH NUMBER**

Lot {number}

**7. EXPIRY DATE**

EXP {month/year}

**8. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**

{Blister}

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Prinovox 100 mg + 25 mg spot-on for medium dogs  
(> 4–10 kg)

**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

Elanco Europe Ltd.  
Distributed by Virbac Limited

**3. EXPIRY DATE**

EXP {month/year}

**4. BATCH NUMBER**

Lot {number}

**5. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only

## **B. PACKAGE LEAFLET**



**PACKAGE LEAFLET:**

**Prinovox 40 mg + 10 mg spot-on solution for small dogs**  
**Prinovox 100 mg + 25 mg spot-on solution for medium dogs**  
**Prinovox 250 mg + 62.5 mg spot-on solution for large dogs**  
**Prinovox 400 mg + 100 mg spot-on solution for extra-large dogs**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER  
AND OF THE MANUFACTURING AUTHORISATION HOLDER  
RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder:

Elanco Europe Ltd.  
Form 2, Bartley Way  
Bartley Wood Business Park  
Hook  
RG27 9XA  
United Kingdom

Distributed by:

Virbac Limited  
Woolpit Business Park  
Windmill Avenue  
Woolpit, Bury St Edmunds  
Suffolk  
IP30 9UP

Manufacturer responsible for batch release:

KVP Pharma + Veterinär Produkte GmbH  
Projensdorfer Str. 324, 24106 Kiel  
Germany

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Prinovox 40 mg + 10 mg spot-on solution for small dogs  
Prinovox 100 mg + 25 mg spot-on solution for medium dogs  
Prinovox 250 mg + 62.5 mg spot-on solution for large dogs  
Prinovox 400 mg + 100 mg spot-on solution for extra-large dogs  
Imidacloprid, Moxidectin

### 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each pipette contains:

Unit Dose	Active substances:		Excipients:	
	Imidacloprid	Moxidectin	Butylhydroxytoluene (E 321)	Benzyl alcohol
0.4 ml	40.0 mg	10.0 mg	0.4 mg	322.9 mg
1.0 ml	100.0 mg	25.0 mg	1.0 mg	807.3 mg
2.5 ml	250.0 mg	62.5 mg	2.5 mg	2018.3 mg
4.0 ml	400.0 mg	100.0 mg	4.0 mg	3229.2 mg

A clear yellow to brownish spot-on solution.

### 4. INDICATION(S)

**For dogs suffering from, or at risk from, mixed parasitic infections:**

- the treatment and prevention of flea infestation (*Ctenocephalides felis*),
- the treatment of biting lice (*Trichodectes canis*),
- the treatment of ear mite infestation (*Otodectes cynotis*), sarcoptic mange (caused by *Sarcoptes scabiei* var. *canis*), demodicosis (caused by *Demodex canis*),
- the prevention of heartworm disease (L3 and L4 larvae of *Dirofilaria immitis*),
- the treatment of circulating microfilariae (*Dirofilaria immitis*),
- the treatment of cutaneous dirofilariosis (adult stages of *Dirofilaria repens*),
- the prevention of cutaneous dirofilariosis (L3 larvae of *Dirofilaria repens*),
- the reduction of circulating microfilariae (*Dirofilaria repens*),
- the prevention of angiostrongylosis (L4 larvae and immature adults of *Angiostrongylus vasorum*),
- the treatment of *Angiostrongylus vasorum* and *Crenosoma vulpis*,
- the prevention of spirocercosis (*Spirocerca lupi*),
- the treatment of *Eucoleus* (syn. *Capillaria*) *boehmi* (adults),
- the treatment of the eye worm *Thelazia callipaeda* (adults),
- the treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of *Toxocara canis*, *Ancylostoma caninum* and *Uncinaria stenocephala*, adults of *Toxascaris leonina* and *Trichuris vulpis*).  
The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

### 5. CONTRAINDICATIONS

Do not use in puppies under 7 weeks of age.

Do not use in cases of known hypersensitivity to the active substances or to any of the excipients.

Do not use in dogs classified as Class 4 for heartworm disease as the safety of the product has not been evaluated in this animal group.

For cats, the corresponding “Prinovox for cat” product, which contains 100 mg/ml imidacloprid and 10 mg/ml moxidectin, must be used.

For ferrets: Do not use Prinovox for dogs. Only “Prinovox for small cats and ferrets” (0.4 ml) must be used.

Do not use on canaries.

## **6. ADVERSE REACTIONS**

Vomiting can occur on rare occasions. Use of the product may result in transient pruritus in dogs. The product may, in rare cases, cause local hypersensitivity reactions. Transient local skin sensitivity reactions including increased itching, hair loss, greasy fur and redness at application site have been reported in very rare cases. These signs disappear without further treatment. In very rare cases, diarrhoea may occur after application of the product. Neurological signs such as ataxia and muscle tremor (most of which are transient) may be observed in very rare cases (see section Overdose (symptoms, emergency procedures, antidotes)).

The product tastes bitter. Salivation may occasionally occur if the animal licks the application site immediately after treatment. This is not a sign of intoxication and disappears within some minutes without treatment. Correct application will minimise licking of the application sites.

The product may in very rare cases cause at the application site a sensation resulting in transient behavioural changes such as lethargy, agitation, and inappetence.

A field study has shown that in heartworm positive dogs with microfilaraemia there is a risk of severe respiratory signs (coughing, tachypnea and dyspnea) that may require prompt veterinary treatment. In the study these reactions were common (seen in 2 of 106 treated dogs). Gastrointestinal signs (vomiting, diarrhoea, inappetence) and lethargy are also common adverse reactions following treatment in such dogs.

In case of accidental oral uptake, symptomatic treatment should be administered by a veterinary surgeon. There is no known specific antidote. The use of activated charcoal may be beneficial.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

## 7. TARGET SPECIES

Dogs

## 8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

For external use only.

Apply topically to the skin.

Dogs up to 25 kg: apply between the shoulder blades.

Dogs of more than 25 kg: apply evenly as 3 or 4 spots along the top of the back.

For details refer to section "ADVICE ON CORRECT ADMINISTRATION".

### *Dosage schedule*

The recommended minimum doses are 10 mg/kg bodyweight imidacloprid and 2.5 mg/kg bodyweight moxidectin, equivalent to 0.1 ml of the product per kg bodyweight.

The treatment schedule should be based on individual veterinary diagnosis and on the local epidemiological situation.

Weight of dog [kg]	Pipette size to be used	Volume [ml]	Imidacloprid [mg/kg bw]	Moxidectin [mg/kg bw]
≤ 4 kg	Prinovox for small dogs	0.4	minimum of 10	minimum of 2.5
> 4–10 kg	Prinovox for medium dogs	1.0	10–25	2.5–6.25
> 10–25 kg	Prinovox for large dogs	2.5	10–25	2.5–6.25
> 25–40 kg	Prinovox for extra-large dogs	4.0	10–16	2.5–4
> 40 kg	appropriate combination of pipettes			

### *Flea treatment and prevention (Ctenocephalides felis)*

One treatment prevents further flea infestation for 4 weeks. Pre-existing pupae in the environment may continue to emerge for 6 weeks or longer after treatment is initiated depending upon climatic conditions. Therefore, it may be necessary to combine the treatment with this product with treatments aimed at breaking the flea life cycle in the surroundings. This can result in more rapid reductions in the household flea population. The product should be administered at monthly intervals when used as part of a treatment strategy for flea allergy dermatitis.

### *Treatment of biting lice (Trichodectes canis)*

A single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.

Treatment of ear mite infestation (*Otodectes cynotis*)

A single dose of the product should be administered. Loose debris should be gently removed from the external ear canal at each treatment. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. Do not apply directly to the ear canal.

Treatment of sarcoptic mange (caused by *Sarcoptes scabiei* var. *canis*)

A single dose should be administered twice 4 weeks apart.

Treatment of demodicosis (caused by *Demodex canis*)

The administration of a single dose every 4 weeks for 2 to 4 months is efficacious against *Demodex canis* and leads to a marked improvement of clinical signs particularly in mild to moderate cases. Especially severe cases may require more prolonged and more frequent treatment. To achieve the best possible response in these severe cases, at the discretion of the veterinarian, the product can be applied once a week and for a prolonged time. In all cases it is essential that the treatment should be continued until skin scrapings are negative on at least 2 consecutive monthly occasions. Treatment should be stopped in dogs that show no improvement or do not respond in mite count after 2 months treatment. Alternative treatment should be administered. Seek the advice of your veterinarian.

As demodicosis is a multi-factorial disease, where possible, it is advisable to also treat any underlying disease appropriately.

Prevention of heartworm disease (*D. immitis*)

Dogs in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore before treatment with this product, the advice provided in the section "SPECIAL WARNING(S)" should be considered.

For prevention of heartworm disease, the product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit *D. immitis* larvae) are present. The product may be administered throughout the year. The first dose may be given after first possible exposure to mosquitoes, but not more than one month after this exposure. The treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month. When replacing another heartworm preventative product in a heartworm prevention programme, the first treatment with this product must be given within 1 month of the last dose of the former medication.

In non-endemic areas there should be no risk of dogs having heartworm. Therefore, they can be treated without special precautions.

Prevention of cutaneous dirofilariosis (skinworm) (*D. repens*)

For prevention of cutaneous dirofilariosis, the product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit *D. repens* larvae) are present. The product may be administered throughout the year or at least 1 month before the first expected exposure to mosquitoes. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month.

Treatment of microfilariae (*D. immitis*)

The product should be administered monthly for two consecutive months.

Treatment of cutaneous dirofilariosis (adult stages of *Dirofilaria repens*)

The product should be administered monthly for six consecutive months.

Reduction of microfilariae (*D. repens*)

The product should be administered monthly for four consecutive months.

Treatment and prevention of *Angiostrongylus vasorum*

A single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. In endemic areas regular monthly applications will prevent angiostrongylosis and patent infection with *Angiostrongylus vasorum*.

Treatment of *Crenosoma vulpis*

A single dose should be administered.

Prevention of *Spirocerca lupi*

The product should be administered monthly.

Treatment of *Eucoleus* (syn. *Capillaria*) *boehmi* (adults)

The product should be administered monthly for two consecutive months. It is advisable to prevent auto-coprophagia between the two treatments in order to prevent possible reinfection.

Treatment of the eye worm *Thelazia callipaeda* (adults)

A single dose of the product should be administered.

Roundworm, hookworm and whipworm treatment


In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective roundworm, hookworms and whipworms. In

areas non-endemic for heartworm, the product can be used as part of a seasonal prevention programme against fleas and gastrointestinal nematodes.

Studies have shown that monthly treatment of dogs will prevent infections caused by *Uncinaria stenocephala*.


## 9. ADVICE ON CORRECT ADMINISTRATION

Remove one pipette from the package. Then hold the pipette in an upright position, and twist and pull off the cap. Reverse the cap and use it to twist and remove the seal from the pipette, as shown.





### For dogs up to 25 kg:

With the dog in a standing position, part the coat between the shoulder blades until the skin is visible. Wherever possible apply to undamaged skin. Place the tip of the pipette on the skin and squeeze the pipette firmly several times to empty its contents directly onto the skin.



### For dogs of more than 25 kg:

For easy application the dog should be standing. The entire contents of the pipette should be applied evenly as 3 or 4 spots along the top of the back, from between the shoulders to the base of the tail. At each spot part the coat until the skin is visible. Wherever possible apply to undamaged skin. Place the tip of the pipette on the skin and gently squeeze the pipette to expel a portion of its contents directly onto the skin. Do not apply an excessive amount of solution at any one spot, as that could cause some of the product to run down the animal's side.



## **10. WITHDRAWAL PERIOD(S)**

Not applicable.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

Do not store above 25 °C.

Do not use this veterinary medicinal product after the expiry date stated on the label and carton. The expiry date refers to the last day of that month.

## **12. SPECIAL WARNING(S)**

Special warning for each target species:

Brief contact of the animal with water on one or two occasions between monthly treatments is unlikely to significantly reduce the efficacy of the product. However, frequent shampooing or immersion of the animal in water after treatment may reduce the efficacy of the product.

Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class. Therefore, the use of this product should be based on the assessment of each individual case and on local epidemiological information about the current susceptibility of the target species in order to limit the possibility of a future selection for resistance.

The use of the product should be based on the confirmed diagnosis of mixed infection (or risk of infection, where prevention applies) at the same time (see also sections 4 and 8).

Efficacy against adult *Dirofilaria repens* has not been tested under field conditions.

Special precautions for use in animals:

Treatment of animals weighing less than 1 kg with 'Prinovox for small dogs' should be based on a benefit-risk assessment.

There is limited experience on the use of the product in sick and debilitated animals, thus the product should only be used based on a benefit-risk assessment for these animals.

Do not apply in the mouth, in the eyes or the ears of the animal.

Care should be taken that the product is not ingested by animals and does not come into contact with the eyes or mouth of the recipient and/or other animals. Consider carefully the correct application method described in section 9, especially that the product should be applied at the base of the skull in order to minimise the risk for the animal to lick the product. When the product is applied in 3 to 4 separate spots (see section 9), specific care should be taken to prevent the animal licking the application sites. Do not allow recently treated animals to groom each other. Do not allow treated animals to come into contact with untreated animals until the application site is dry.



This product contains moxidectin (a macrocyclic lactone), therefore special care should be taken with Collie or Old English Sheep dogs and related breeds or crossbreeds, to correctly administer the product as described under the section “ADVICE ON CORRECT ADMINISTRATION”; in particular, oral uptake by the recipient and/or other animals in close contact should be prevented.

The safety of the product has only been evaluated in dogs classified as either Class 1 or 2 for heartworm disease in laboratory studies and in a few Class 3 dogs in a field study. Therefore the use in dogs with obvious or severe symptoms of the disease should be based on a careful benefit risk assessment by the treating veterinarian.

Although experimental overdosage studies have shown that the product may be safely administered to dogs infected with adult heartworms, it has no therapeutic efficacy against adult *Dirofilaria immitis*. It is therefore recommended that all dogs 6 months of age or more, living in areas endemic for heartworm, should be tested for existing adult heartworm infection before being treated with the product. At the discretion of the veterinarian, infected dogs should be treated with an adulticide to remove adult heartworms. The safety of the product has not been evaluated when administered on the same day as an adulticide.

Imidacloprid is toxic for birds, especially canaries.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Avoid contact with skin, eyes or mouth.

Do not eat, drink or smoke during application.

Ingestion of the product is harmful. In order to prevent children getting access to pipettes, keep the pipette in the original packaging until ready for use and dispose of used pipettes immediately.

Wash hands thoroughly after use.

After application, treated animals should not be handled, especially by children, until the application site is dry. This may be ensured by treating animals in the evening.

Do not allow recently treated animals to sleep with owners, especially children.

In case of accidental spillage onto skin, wash off immediately with soap and water.

People with a known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the product with caution. In very rare cases the product may cause skin sensitisation or transient skin reactions (for example numbness, irritation or burning/tingling sensation).

In very rare cases the product may cause respiratory irritation in sensitive individuals. If the product accidentally gets into eyes, they should be thoroughly flushed with water.

In case of accidental ingestion of the product or if skin or eye symptoms persist, seek medical advice immediately and show the package leaflet or label to the physician.

Environmental information/warnings

Moxidectin fulfils the criteria for a persistent, bioaccumulative and toxic substance; therefore, exposure of the environment to moxidectin should be minimised as much as possible. The product should not enter water courses as it has harmful effects on aquatic organisms. Moxidectin is highly toxic to aquatic organisms. Dogs should not be allowed to swim in surface waters for 4 days after treatment.

### Other precautions

The solvent in this product may stain or damage certain materials including leather, fabrics, plastics and finished surfaces. Allow the application site to dry before permitting contact with such materials.

### Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation in the target species. Therefore, the use of the product is not recommended in animals intended for breeding or during pregnancy and lactation.

### Interaction with other medicinal products and other forms of interaction:

During treatment with this veterinary medicinal product no other antiparasitic macrocyclic lactone should be administered.

No interactions between this veterinary medicinal product and routinely used veterinary medicinal products or medical or surgical procedures have been observed.

Safety of this veterinary medicinal product when administered on the same day as an adulticide to remove adult heartworms has not been evaluated.

### Overdose (symptoms, emergency procedures, antidotes):

Up to 10 times the recommended dose was tolerated in adult dogs with no evidence of adverse effects or undesirable clinical signs. Five times the recommended minimum dose applied at weekly intervals for 17 weeks was investigated in dogs aged over 6 months and tolerated with no evidence of adverse effects or undesirable clinical signs.

The product was administered to puppies at up to 5 times the recommended dose, every 2 weeks for 6 treatments, and there were no serious safety concerns. Transient mydriasis, salivation, vomiting and transient rapid respiration were observed.

After accidental oral ingestion or overdose, neurological signs (most of which are transient) such as ataxia, generalised tremors, ocular signs (dilated pupils, little pupillary reflex, nystagmus), abnormal respiration, salivation and vomiting may occur in very rare cases.

Ivermectin-sensitive Collie dogs tolerated up to 5 times the recommended dose repeated at monthly intervals without any adverse effects, but the safety of application at weekly intervals has not been investigated in ivermectin-sensitive Collie dogs. When 40 % of the unit dose was given orally, severe neurological signs were observed. Oral administration of 10 % of the recommended dose produced no adverse effects.

Dogs infected with adult heartworms tolerated up to 5 times the recommended dose, every 2 weeks for 3 treatments, without any adverse effects.

In case of accidental oral uptake, symptomatic treatment should be administered. There is no known specific antidote. The use of activated charcoal may be beneficial.

Incompatibilities:

None known.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Medicines should not be disposed of via wastewater or household waste. The product should not enter water courses as this may be dangerous for fish and other aquatic organisms. Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

November 2021

**15. OTHER INFORMATION**


Imidacloprid is effective against larval flea stages and adult fleas. Flea larvae in the pet's surroundings are killed after contact with a pet treated with the product.

The drug has a persistent action and protects dogs for 4 weeks after a single application against re-infection with the following parasites: *Dirofilaria immitis*, *Dirofilaria repens*, *Angiostrongylus vasorum*.

Studies evaluating the pharmacokinetic behaviour of moxidectin after multiple applications have indicated that steady state serum levels are achieved following approximately 4 consecutive monthly treatments in dogs.

Pack sizes: 0.4 ml, 1.0 ml, 2.5 ml and 4.0 ml per pipette.  
Blister packs containing 1, 2, 3, 4, 6 or 21 pipettes.  
Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.



Approved: 09 February 2022